Kazakhstan creates new opportunities for European manufacturers

A more accessible market for European companies

ACIR Southern Europe participated in a strategic event bringing together Kazakhstan’s Ministry of Health, regulatory authorities and senior executives from leading global pharmaceutical companies. The format highlighted a clear policy direction: the government is prioritizing direct dialogue with manufacturers and reducing reliance on intermediaries.

For the European companies represented by ACIR, this creates a faster and more efficient path into one of Central Asia’s most promising pharmaceutical markets.

Regulatory reforms with immediate business impact

Several important reforms were presented during the event:

1. Accelerated registration for medicines already approved in the European Union, with timelines reduced to as little as 15 days.
2. Pricing reform offering greater commercial flexibility.
3. Direct public procurement from manufacturers.
4. Digital serialization and analytics improving transparency and demand visibility.
5. State-initiated registration for essential medicines.
6. Stronger compliance requirements aligned with Eurasian Economic Union standards.

Why partnering with ACIR Southern Europe matters

These developments create significant opportunities for European laboratories seeking to export, register products or establish local partnerships in Kazakhstan and across Central Asia. ACIR Southern Europe acts as a strategic partner by providing:

• regulatory and commercial analysis;
• local partner identification;
• financing support;
• public tender participation;
• technology transfer and production projects.